These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16708557)

  • 1. [The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone].
    Pawlik A; Czerny B; Dabrowska-Zamojcin E; Górnik W; Poziomkowska I; Gawrońska-Szklarz B; Herczyńska M
    Pol Arch Med Wewn; 2005 Sep; 114(3):843-7. PubMed ID: 16708557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-6 promoter polymorphism in patients with rheumatoid arthritis.
    Pawlik A; Wrzesniewska J; Florczak M; Gawronska-Szklarz B; Herczynska M
    Scand J Rheumatol; 2005; 34(2):109-13. PubMed ID: 16095005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6 gene -174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis.
    Palomino-Morales R; Gonzalez-Juanatey C; Vazquez-Rodriguez TR; Miranda-Filloy JA; Llorca J; Martin J; Gonzalez-Gay MA
    Clin Exp Rheumatol; 2009; 27(6):964-70. PubMed ID: 20149313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of methotrexate on the gene expression of the pro-inflammatory cytokine IL-12A in the therapy of rheumatoid arthritis.
    Hobl EL; Mader RM; Erlacher L; Duhm B; Mustak M; Bröll H; Högger P; Kalipciyan M; Jilma B
    Clin Exp Rheumatol; 2011; 29(6):963-9. PubMed ID: 22133036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
    Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
    Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis.
    Fabris M; Tolusso B; Di Poi E; Assaloni R; Sinigaglia L; Ferraccioli G
    J Rheumatol; 2002 Sep; 29(9):1847-50. PubMed ID: 12233877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL1beta+3953 exon 5 and IL-2 -330 promoter polymorphisms in patients with rheumatoid arthritis.
    Pawlik A; Kurzawski M; Florczak M; Gawronska Szklarz B; Herczyńska M
    Clin Exp Rheumatol; 2005; 23(2):159-64. PubMed ID: 15895884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The -590 IL-4 promoter polymorphism in patients with rheumatoid arthritis.
    Pawlik A; Wrzesniewska J; Florczak M; Gawronska-Szklarz B; Herczynska M
    Rheumatol Int; 2005 Nov; 26(1):48-51. PubMed ID: 15660235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-18 gene (IL18) promoter polymorphisms in patients with rheumatoid arthritis.
    Pawlik A; Kurzawski M; Drozdzik M; Dziedziejko V; Safranow K; Herczynska M
    Scand J Rheumatol; 2009; 38(3):159-65. PubMed ID: 19229765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTPN22 1858C>T polymorphism is strongly associated with rheumatoid arthritis but not with a response to methotrexate therapy.
    Majorczyk E; Pawlik A; Kuśnierczyk P
    Int Immunopharmacol; 2010 Dec; 10(12):1626-9. PubMed ID: 20888443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 10 and tumor necrosis factor-alpha genotypes in rheumatoid arthritis--association with clinical response to glucocorticoids.
    de Paz B; Alperi-López M; Ballina-García FJ; Prado C; Mozo L; Gutiérrez C; Suárez A
    J Rheumatol; 2010 Mar; 37(3):503-11. PubMed ID: 20080912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
    Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Breedveld FC; Dijkmans BA;
    Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-77-82. PubMed ID: 17083767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study).
    Wevers-de Boer K; Visser K; Heimans L; Ronday HK; Molenaar E; Groenendael JH; Peeters AJ; Westedt ML; Collée G; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
    Ann Rheum Dis; 2012 Sep; 71(9):1472-7. PubMed ID: 22402145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis.
    Fabris M; Quartuccio L; Lombardi S; Saracco M; Atzeni F; Carletto A; Cimmino M; Fabro C; Pontarini E; Pellerito R; Bambara LM; Sarzi-Puttini P; Cutolo M; Manfredi M; Benucci M; Morassi P; Fischetti F; Padovan M; Govoni M; Curcio F; Tonutti E; De Vita S
    Autoimmun Rev; 2012 Mar; 11(5):315-20. PubMed ID: 20974296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
    Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
    Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-10 promoter polymorphism in patients with rheumatoid arthritis.
    Pawlik A; Kurzawski M; Szklarz BG; Herczynska M; Drozdzik M
    Clin Rheumatol; 2005 Sep; 24(5):480-4. PubMed ID: 15915323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoids in the treatment of rheumatoid arthritis: still used after 65 years.
    Bijlsma JW; Jacobs JW
    Ann N Y Acad Sci; 2014 May; 1318():27-31. PubMed ID: 24641732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs.
    Drozdzik M; Rudas T; Pawlik A; Kurzawski M; Czerny B; Gornik W; Herczynska M
    Eur J Clin Pharmacol; 2006 Nov; 62(11):933-7. PubMed ID: 16932953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of interleukin-4 gene polymorphisms and interleukin-4 serum level on susceptibility and severity of rheumatoid arthritis in Egyptian population.
    Hussein YM; El-Shal AS; Rezk NA; Abdel Galil SM; Alzahrani SS
    Cytokine; 2013 Mar; 61(3):849-55. PubMed ID: 23394902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy.
    Tolusso B; Pietrapertosa D; Morelli A; De Santis M; Gremese E; Farina G; Carniello SG; Del Frate M; Ferraccioli G
    Pharmacogenomics; 2006 Jul; 7(5):683-95. PubMed ID: 16886894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.